Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance

 Sales growth of 6.7% at CER and business EPS⁽¹⁾ of €1.78

• Dupixent sales up 24.9% to €2,835 million, on target to deliver ~€13bn in 2024
• Pharma launches up 90.5% to €606 million, led by Nexviazyme and ALTUVIIIO
• Vaccines sales up 5.6%, boosted by Beyfortus
• Consumer Healthcare (CHC) up 9.0%, benefiting from the Qunol acquisition in Physical and Mental Wellness and strong Digestive Wellness performance
• R&D expenses grew 11.8%, reflecting strategic shift of resources into development
• SG&A expenses grew 2.9%, less than sales growth
• Business EPS⁽¹⁾ of €1.78, down 17.6% reported and 7.4% at CER
• IFRS EPS of €0.91, down 43.1% reported

R&D transformation advanced further

• Three regulatory approvals: new Dupixent indications in the US and Japan and Beyfortus in Japan
• Positive phase 3 results for rilzabrutinib in immune thrombocytopenia, a rare disease
• Reaffirming increasing pipeline news flow over 2024-2025, including 12 phase 3 data readouts

Corporate Social Responsibility progress

• Sanofi Global Health Unit: making a difference for patients in low- and middle-income countries
• Cancer and work: Sanofi supporting health and wellbeing in the workplace

Business EPS guidance reiterated

• Sanofi expects 2024 business EPS⁽¹⁾ to remain roughly stable excluding the impact of an expected effective tax rate increase to 21% and decrease low single-digit⁽²⁾ at CER including the higher expected tax rate, barring unforeseen major adverse events. Applying average April 2024 exchange rates, the currency impact on 2024 business EPS is estimated between -5.5% to -6.5%.

https://www.biospace.com/article/releases/press-release-sanofi-q1-robust-7-percent-sales-growth-driven-by-launches-underpins-full-year-guidance/